These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32914324)

  • 1. Optical Coherence Tomography Biomarkers of Inflammation in Diabetic Macular Edema Treated by Fluocinolone Acetonide Intravitreal Drug-Delivery System Implant.
    Arrigo A; Capone L; Lattanzio R; Aragona E; Zollet P; Bandello F
    Ophthalmol Ther; 2020 Dec; 9(4):971-980. PubMed ID: 32914324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
    Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
    Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study.
    Mathis T; Papegaey M; Ricard C; Rezkallah A; Matonti F; Sudhalkar A; Vartin C; Dot C; Kodjikian L
    Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME).
    McCluskey JD; Kaufman PL; Wynne K; Lewis G
    Int Med Case Rep J; 2019; 12():93-102. PubMed ID: 31114396
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
    El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
    Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optical Coherence Tomography Biomarkers: Vitreous Status Influence in Outcomes for Diabetic Macular Edema Therapy with 0.19-mg Fluocinolone Acetonide Implant.
    Pessoa B; Ferreira A; Leite J; Figueira J; Meireles A; Beirão JM
    Ophthalmic Res; 2021; 64(4):639-647. PubMed ID: 33601389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Foveal Eversion: A Possible Biomarker of Persistent Diabetic Macular Edema.
    Arrigo A; Aragona E; Capone L; Lattanzio R; Zollet P; Bandello F
    Ophthalmol Ther; 2021 Mar; 10(1):115-126. PubMed ID: 33420954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve.
    Kessler LJ; Auffarth GU; Khoramnia R
    J Ocul Pharmacol Ther; 2023 Sep; 39(7):449-455. PubMed ID: 37384926
    [No Abstract]   [Full Text] [Related]  

  • 9. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
    Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
    Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Foveal eversion patterns in diabetic macular edema.
    Arrigo A; Saladino A; Aragona E; Amato A; Capone L; Bianco L; Lattanzio R; Bandello F; Battaglia Parodi M
    Sci Rep; 2022 Jul; 12(1):13097. PubMed ID: 35907954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE.
    Elbarky AM
    Clin Ophthalmol; 2020; 14():823-830. PubMed ID: 32214793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema.
    Eaton A; Koh SS; Jimenez J; Riemann CD
    Ophthalmol Ther; 2019 Mar; 8(1):51-62. PubMed ID: 30560505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
    Holden SE; Kapik B; Beiderbeck AB; Currie CJ
    Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series.
    Schmit-Eilenberger VK
    Clin Ophthalmol; 2015; 9():801-11. PubMed ID: 25999689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenging Clinical Cases - A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN
    Pessoa B; Melo-Beirão J; Meireles A; Menéres P
    Int Med Case Rep J; 2020; 13():437-448. PubMed ID: 32982484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic biomarkers of chronic diabetic macular edema treated with a fiuocinolone acetonide intravitreal implant.
    Lopes BO; Brizido MS; Aerts F; Pina SM; Simoes PS; Miranda MI
    Med Hypothesis Discov Innov Ophthalmol; 2021; 10(2):50-58. PubMed ID: 37641614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world experience with fluocinolone acetonide intravitreal implant in patients with diabetic macular edema.
    Capone L; Airaghi P; Aragona P; Castellino N; Cicinelli MV; Ciucci F; Coppola M; Gaetano C; Lattanzio R; Lorusso M; Maceroni M; Malvasi ME; Marco L; Marraffa M; Martini G; Mastropasqua R; Minnella AM; Nikolopulou E; Ortisi E; Pacella E; Papa V; Pennesi C; Reibaldi M; Rizzo S; Toto L; Trombetta L; Bandello F
    Eur J Ophthalmol; 2024 Feb; ():11206721241235266. PubMed ID: 38396370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema.
    Elaraoud I; Attawan A; Quhill F
    Ophthalmol Ther; 2016 Jun; 5(1):95-104. PubMed ID: 26885863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluocinolone acetonide 0.19 mg intravitreal implant improves foveal thickness and reduces treatment burden for up to 1 year in eyes with persistent diabetic macular edema.
    Coney JM
    Int Med Case Rep J; 2019; 12():161-169. PubMed ID: 31213929
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of 190 mcg fluocinolone acetonide intravitreal implant: microperimetry and OCT real-life data.
    Avogaro F; Florido A; Calandri A; Toja F; Vingolo EM
    Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):1759-1766. PubMed ID: 36930491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.